imatinib mesylate has been researched along with Aplasia Pure Red Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asou, H; Iwato, K; Kimura, A; Tanaka, H | 1 |
| Jin, J; Li, Y; Meng, HT; Qian, WB; Yang, CM | 1 |
2 other study(ies) available for imatinib mesylate and Aplasia Pure Red Cell
| Article | Year |
|---|---|
Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
Topics: Adult; Benzamides; Chronic Disease; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Red-Cell Aplasia, Pure | 2010 |
Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Cell Count; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Red-Cell Aplasia, Pure | 2007 |